Overview

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Status:
Completed
Trial end date:
2017-01-23
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals